Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, N. H. | - |
dc.contributor.author | Choi, J. | - |
dc.contributor.author | Choi, K. M. | - |
dc.contributor.author | Baik, S. H. | - |
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Kim, S. G. | - |
dc.date.accessioned | 2021-09-02T07:30:37Z | - |
dc.date.available | 2021-09-02T07:30:37Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-09 | - |
dc.identifier.issn | 1262-3636 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/73680 | - |
dc.description.abstract | Aims. - This study examined whether dipeptidyl peptidase (DPP)-4 inhibitor use is beneficial or harmful to diabetic retinopathy (DR) compared with other glucose-lowering agents in patients with type 2 diabetes (T2D). Methods. - From a population-based cohort provided by the National Health Insurance Service in Korea, 67,743 adults with T2D were identified as having been treated with oral glucose-lowering agents between 2008 and 2013. Matching (1:1) was performed for two groups comparing ever-use (cases) and never-use (controls) of DPP-4 inhibitors (n = 14,522 in each group). Cox regression analyses were used to assess risk of the following DR events: vitreous haemorrhage; vitrectomy or photocoagulation; intravitreal agent use; and blindness. Results. - During a median follow-up of 28.4 (14.0-45.2) months, there were 305 (in controls) and 342 (in cases) composite DR events. DPP-4 inhibitor ever-use was not associated with overall risk of composite DR events [adjusted hazard ratio (HR): 1.08, 95% CI: 0.93-1.261 compared with never-use, nor was the risk of each DR outcome increased with DPP-4 inhibitor therapy either. However, DPP-4 inhibitor administration for < 12 months was associated with a greater risk of composite DR events (adjusted HR: 1.31, 95% CI: 1.09-1.57) compared with other glucose-lowering agents over the same treatment period. Conclusion. - In comparison to other oral glucose-lowering agents, DPP-4 inhibitor treatment did not increase overall risk of DR. However, DPP-4 inhibitors may be associated with an increased risk of retinopathy events early in the treatment phase. (C) 2018 Elsevier Masson SAS. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MASSON EDITEUR | - |
dc.subject | BLOOD-GLUCOSE CONTROL | - |
dc.subject | CARDIOVASCULAR OUTCOMES | - |
dc.subject | HEART-FAILURE | - |
dc.subject | TYPE-2 | - |
dc.subject | MULTICENTER | - |
dc.subject | SITAGLIPTIN | - |
dc.subject | THERAPIES | - |
dc.title | Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, N. H. | - |
dc.contributor.affiliatedAuthor | Lee, J. | - |
dc.contributor.affiliatedAuthor | Kim, S. G. | - |
dc.identifier.doi | 10.1016/j.diabet.2018.03.004 | - |
dc.identifier.scopusid | 2-s2.0-85046660016 | - |
dc.identifier.wosid | 000447960300008 | - |
dc.identifier.bibliographicCitation | DIABETES & METABOLISM, v.44, no.4, pp.361 - 367 | - |
dc.relation.isPartOf | DIABETES & METABOLISM | - |
dc.citation.title | DIABETES & METABOLISM | - |
dc.citation.volume | 44 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 361 | - |
dc.citation.endPage | 367 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | BLOOD-GLUCOSE CONTROL | - |
dc.subject.keywordPlus | CARDIOVASCULAR OUTCOMES | - |
dc.subject.keywordPlus | HEART-FAILURE | - |
dc.subject.keywordPlus | TYPE-2 | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | SITAGLIPTIN | - |
dc.subject.keywordPlus | THERAPIES | - |
dc.subject.keywordAuthor | Diabetic retinopathy | - |
dc.subject.keywordAuthor | Dipeptidyl peptidase-4 inhibitors | - |
dc.subject.keywordAuthor | Type 2 diabetes | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.